In this article, we will discuss Amsacrine (Toxic Effects in Humans- 2). So, let’s get started.
In phase II studies with amsacrine as a single agent in patients with solid tumours,
myelosuppression was again the dose-limiting effect (90–120 mg/m2 once every three to four weeks), with leukopenia and thrombocytopenia occurring in almost all patients. Anaemia is also common. At these doses, the leukopenia is mild to moderate in most
patients but more severe in around 30% of patients (Hornedo & Van Echo, 1985). The
lowest counts usually occur at about day 10, with recovery by day 21. Myelosuppression is usually more severe in previously treated patients, and is much more severe with high doses of amsacrine (600–1000 mg/m2)